RxDoctor Payments DataLook up a doctor →

Deepa Nidhiry, MD

Neurology · Danville, KYNPI 1932305778

Payments from drug & device makers

$22,524in general payments, 2019–2025

Across 963 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Amgen$4K
  • Teva Pharmaceuticals USA, Inc.$1K
  • UCB, Inc.$902
  • Pfizer$831
  • Biogen$719
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$3,20014%
  • Speaking & faculty fees$1,9599%
  • Food & beverage$16,82275%
  • Education$5432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)169$4,000
Amgen31$3,762
Teva Pharmaceuticals USA, Inc.45$1,322
UCB, Inc.39$902
Pfizer68$831
Biogen37$719
Novartis44$710
Vanda Pharmaceuticals Inc.14$631
Lilly USA, LLC29$551
Sunovion Pharmaceuticals Inc.38$504
SK Life Science, Inc.26$494
Biohaven Pharmaceuticals, Inc.28$449
Bristol Myers Squibb26$406
Acadia Pharmaceuticals Inc20$369
Upsher-smith Laboratories LLC17$337
Harmony Biosciences LLC17$329
AstraZeneca(2 entities)15$319
Genentech USA, Inc.18$298
Eisai Inc.15$281
Lundbeck LLC13$278
EMD Serono, Inc.14$276
Neurelis, Inc.18$271
CSL Behring13$252
Catalyst Pharmaceuticals, Inc.12$249
MDD US Operations, LLC15$249
Biohaven Pharmaceutical Holding Company Ltd.13$207
Amneal Pharmaceuticals LLC11$183
Grifols USA, LLC8$175
GT Medical Technologies, Inc1$172
Argenx US, Inc.8$169
Neurocrine Biosciences, Inc.7$158
Aprecia Pharmaceuticals, LLC9$157
Johnson & Johnson(2 entities)8$152
Sirtex Medical Inc1$140
TG Therapeutics, Inc.7$121
Scilex Pharmaceuticals Inc.6$120
Livanova USA, Inc.6$117
Azurity Pharmaceuticals, Inc.7$112
DIXI Medical USA Corp1$103
Alnylam Pharmaceuticals Inc.5$102
Otsuka America Pharmaceutical, Inc.5$100
Acorda Therapeutics, Inc6$90
Avion Pharmaceuticals4$88
Impel Pharmaceuticals Inc.5$85
Takeda Pharmaceuticals U.S.A., Inc.3$82
Merz Pharmaceuticals, LLC4$81
Arbor Pharmaceuticals, Inc.5$80
Boston Scientific4$73
Endo Pharmaceuticals Inc.4$72
Axsome Therapeutics, Inc.3$69
Sumitomo Pharma America, Inc.3$64
Aucta Pharmaceuticals, Inc.3$60
ANI Pharmaceuticals, Inc.2$54
Coherus Oncology, Inc.3$51
Tonix Medicines, Inc.2$43
Avanir Pharmaceuticals, Inc.3$42
Zyla Life Sciences, Inc.3$41
Kyowa Kirin, Inc.2$40
Supernus Pharmaceuticals, Inc.2$36
Merz North America, Inc.2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,524 in reported general payments places this provider in the 75th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$70,297
Medicare patients
275
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$102,859
QuliptaAtogepant70$76,771
UbrelvyUbrogepant37$36,065
AptiomEslicarbazepine Acetate15$34,891
OnfiClobazam12$30,218
Nurtec OdtRimegepant Sulfate20$25,215
Emgality PenGalcanezumab-Gnlm20$24,742
VimpatLacosamide31$24,097
BriviactBrivaracetam13$19,865
Lacosamide79$19,001
Levetiracetam273$11,962
Aimovig AutoinjectorErenumab-Aooe15$10,831
Memantine Hcl175$4,775
Levetiracetam ErLevetiracetam36$4,614
Carbidopa-LevodopaCarbidopa/Levodopa156$4,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$4,000$112,836107 claims
Neurocrine Biosciences, Inc.Ingrezza$158$102,85913 claims
UCB, Inc.Vimpat, Briviact$902$43,96244 claims
Sunovion Pharmaceuticals Inc.Aptiom$504$34,89115 claims
Lundbeck LLCOnfi$278$30,21812 claims
PfizerNurtec Odt$831$25,21520 claims
Upsher-smith Laboratories LLCTopiramate$337$1,602206 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 neurology providers in Kentucky.

Other neurology in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →